IDEXX Laboratories, Inc. $IDXX Shares Sold by Villere ST Denis J & Co. LLC

Villere ST Denis J & Co. LLC lessened its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 25.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 42,204 shares of the company’s stock after selling 14,037 shares during the period. IDEXX Laboratories accounts for approximately 2.6% of Villere ST Denis J & Co. LLC’s investment portfolio, making the stock its 16th biggest position. Villere ST Denis J & Co. LLC owned about 0.05% of IDEXX Laboratories worth $26,964,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of IDXX. WealthCollab LLC acquired a new stake in shares of IDEXX Laboratories in the second quarter valued at approximately $30,000. J.Safra Asset Management Corp purchased a new stake in shares of IDEXX Laboratories in the third quarter valued at about $31,000. Armstrong Advisory Group Inc. increased its position in IDEXX Laboratories by 55.9% during the third quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock worth $34,000 after purchasing an additional 19 shares during the last quarter. Salomon & Ludwin LLC purchased a new position in IDEXX Laboratories during the third quarter worth about $35,000. Finally, Greykasell Wealth Strategies Inc. purchased a new position in IDEXX Laboratories during the third quarter worth about $35,000. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Performance

NASDAQ IDXX opened at $639.60 on Tuesday. The company has a market cap of $51.07 billion, a P/E ratio of 50.72, a P/E/G ratio of 3.58 and a beta of 1.67. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $769.98. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.18 and a quick ratio of 0.87. The stock has a 50-day moving average of $703.10 and a two-hundred day moving average of $662.65.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Monday, February 2nd. The company reported $3.08 earnings per share for the quarter, topping analysts’ consensus estimates of $2.93 by $0.15. The business had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a return on equity of 67.78% and a net margin of 24.65%.The company’s revenue was up 14.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.53 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. As a group, analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Insider Buying and Selling at IDEXX Laboratories

In related news, EVP Nimrata Hunt sold 9,425 shares of the business’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $703.34, for a total transaction of $6,628,979.50. Following the completion of the transaction, the executive vice president owned 21,149 shares in the company, valued at approximately $14,874,937.66. The trade was a 30.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.98% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Weiss Ratings cut shares of IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday. Stifel Nicolaus set a $775.00 price objective on IDEXX Laboratories in a research report on Monday, November 3rd. BTIG Research set a $800.00 target price on IDEXX Laboratories in a research note on Tuesday. Morgan Stanley upped their price target on IDEXX Laboratories from $765.00 to $805.00 and gave the company an “overweight” rating in a research note on Tuesday, November 4th. Finally, Barclays began coverage on shares of IDEXX Laboratories in a report on Monday, December 8th. They issued an “overweight” rating and a $850.00 price objective on the stock. Seven equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $760.50.

Key Stories Impacting IDEXX Laboratories

Here are the key news stories impacting IDEXX Laboratories this week:

• Positive Sentiment: Q4 beat: IDXX posted $3.08 EPS (vs. $2.93 consensus) and $1.091B in revenue (up ~14% YoY), with expanding margins — a sign of continued underlying demand and efficiency. IDEXX Laboratories Announces Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Management cites resilient demand at vet clinics and higher testing per visit; it says 2026 revenue and profit are expected to come in above Wall Street’s prior estimates. IDEXX forecasts 2026 revenue, profit above estimates on strong demand for pet diagnostics
• Neutral Sentiment: Guidance is mixed: FY‑2026 EPS was guided to a range (14.290–14.800) that overlaps the consensus (≈14.45), and revenue guidance sits at the low end of estimates ($4.6–4.7B), leaving room for investor interpretation on growth pacing.
• Negative Sentiment: Market reaction: despite the beat, shares sold off in early trading — indicating investors were disappointed by the tone or range of guidance (or rotated out after the run‑up). IDEXX Stock Down Despite Q4 Earnings & Revenue Beat, Margins Rise
• Negative Sentiment: Valuation risk: IDXX trades at an elevated P/E, which can amplify downside when guidance is viewed as conservative or when growth expectations are re‑priced.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.